Business
Second Sight to Discuss Fourth Quarter and Year-End 2019 Financial Results on March 19, 2020 Conference Call
LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer
About this update from Vivani Medical, Inc.
[{"type":"text","content":" LOS ANGELES--(BUSINESS WIRE)--\nSecond Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its 2019 fourth quarter and year-end financial results on Thursday, March 19, 2020, after the close of the U.S. financial markets.\n\n\nWill McGuire, President and Chief Executive Officer, John T. Blake, Chief Financial Officer, and Pat Ryan, Chief Operating Officer, will host a conference call to discuss the results as follows:\n\n\n\n\nDate\n\n\n\nThursday, March 19, 2020\n\n\n\n\n\nTime\n\n\n\n4:30 p.m. ET\n\n\n\n\n\nToll free (U.S.)\n\n\n\n(800) 710-8126\n\n\n\n\n\nInternational\n\n\n\n(720) 634-2491\n\n\n\n\n\nWebcast (live and replay)\n\n\n\nwww.secondsight.com under the ‘Investors’ section.\n\n\n\n\n\nThe archived webcast will be available for 30 days via the aforementioned URL.\n\n\nAbout Second Sight\n\n\nSecond Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s U.S. headquarters are in Los Angeles, California. More information is available at www.secondsight.com.\n\n\nAbout the Orion Visual Cortical Prosthesis System\n\n\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feas...